Arkolith/Insider Trading/GANX/Form 4

Alder Matthias

Chief Executive Officer, DirectorGain Therapeutics, Inc. (GANX) · full profile →Form 4 · filed Dec 22, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$507
Net Open-Market Flow
-$507
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 21, 2023Sell(S)206$2.46$5075K
Dec 20, 2023Option exercise(M)637——5K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 20, 2023Option exercise(M)637—$07K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-059558) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Gain Therapeutics, Inc.

Build

Ask your agent about GANX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001209191-23-059558"
Ask your agent
Use Arkolith to summarize insider buying and selling at Gain Therapeutics, Inc.
over the last 90 days and cite the filings.